Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Pioglitazone is an approved anti-hyperglycemic medication and is thought to have anti-inflammatory properties. This study seeks to gather safety and tolerability data related to pioglitazone when given to patients who require hospital admission for confirmed positive COVID-19 infections with elevated blood sugar levels as compared to patients who did not receive pioglitazone during their hospitalization for COVID-19.
Description: Number and type of adverse events
Measure: Adverse events outcomes without attribution Time: Baseline, until 30 days after last doseDescription: Number and type of adverse events
Measure: Adverse events attributable Time: Baseline, until 30 days after last doseDescription: Disease severity as measured by 7 point ordinal scale
Measure: Clinical improvement Time: Baseline, until 30 days after last doseDescription: Type of oxygen support treatment
Measure: Levels of treatment Time: Baseline, until 30 days after last doseDescription: Change from Baseline of d-Dimer
Measure: d-Dimer Time: Baseline, until 30 days after last doseDescription: Change from Baseline of CRP
Measure: C Reactive Protein Time: Baseline, until 30 days after last doseDescription: Change from Baseline of Ferritin
Measure: Ferritin Time: Baseline, until 30 days after last doseDescription: Change from Baseline of Lactate dehydrogenase
Measure: Lactate dehydrogenase Time: Baseline, until 30 days after last doseDescription: Change from Baseline of A1c
Measure: A1c Time: Baseline, until 30 days after last doseAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports